NCT01405157View on ClinicalTrials.gov

A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets Under Fasting Conditions

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 1, 2012

Primary Completion Date

February 20, 2012

Study Completion Date

February 20, 2012

Conditions
Therapeutic Equivalency
Interventions
DRUG

methylprednisolone

constituted powder for oral suspension 4 mg/mL single dose at 16 mg

DRUG

methylprednisolone

tablets 16 mg single dose

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01405157 - A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter